Sectors

CTXR
Citius Pharmaceuticals, Inc.
0.60
2 x 0.41
2 x 0.78
bid
ask
+
0.02
2.85%
2 @ 07:30 PM
0.59 -0.01 (1.18%)
Ytd-22.78%
1y-48.72%
0.58
day range
0.60
0.48
52 week range
1.82
Open0.60Prev Close0.58Low0.58High0.60Mkt Cap16.47M
Vol284.09KAvg Vol544.29KEPS-1.75P/EN/AForward P/E15.32
Beta1.66Short Ratio1.23Inst. Own13.17%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1450-d Avg0.59200-d Avg0.741yr Est54.00
Income Statement
Total Revenue1.49M
Revenues (USD)1.49M
Cost of Revenue491.84K
Gross Profit1.00M
Operating Expenses12.73M
Research and Development Expense1.05M
Selling, General and Administrative Expense6.15M
Operating Income-11.73M
Interest Expense231.73K
Income Tax Expense-107.35K
Net Income-8.86M
Net Income Common Stock-8.86M
Net Income Common Stock (USD)-8.86M
Consolidated Income-11.92M
Net Income to Non-Controlling Interests-3.06M
Earnings per Basic Share-0.34
Earnings per Basic Share (USD)-0.34
Earnings per Diluted Share-0.34
Earning Before Interest & Taxes (EBIT)-8.74M
Earning Before Interest & Taxes (USD)-8.74M
Weighted Average Shares26.17M
Weighted Average Shares Diluted26.17M
Balance Sheet
Cash and Equivalents17.05M
Cash and Equivalents (USD)17.05M
Trade and Non-Trade Receivables686.24K
Current Assets43.33M
Property, Plant & Equipment Net753.04K
Total Assets142.26M
Debt Current176.17K
Total Debt7.18M
Current Liabilities51.65M
Debt Non-Current7.00M
Total Liabilities66.35M
Accumulated Retained Earnings (Deficit)-277.12M
Shareholders Equity66.61M
Shareholders Equity (USD)66.61M
Assets Non-Current98.92M
Total Debt (USD)7.18M
Goodwill and Intangible Assets9.35M
Inventory22.63M
Liabilities Non-Current14.70M
Trade and Non-Trade Payables23.69M
Tax Liabilities7.70M
Cash Flow
Depreciation, Amortization & Accretion41.48K
Net Cash Flow from Financing23.09M
Net Cash Flow / Change in Cash & Cash Equivalents12.42M
Capital Expenditure-2.00M
Issuance (Purchase) of Equity Shares14.18M
Issuance (Repayment) of Debt Securities 9.64M
Net Cash Flow from Investing-2.00M
Net Cash Flow from Operations-8.68M
Share Based Compensation3.81M